VEGFA and meningioma: In this regard, Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), has been investigated as a therapeutic option for recurrent meningiomas, given the tumors’ reliance on angiogenesis.[39] Clinical studies have yielded mixed outcomes regarding its efficacy.